Lyell Immunopharma, Inc. (LYEL) has a negative trailing P/E of -1.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -66.90%.
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -32.2 | 0.00 | 10.21 | 6,339.02 | - |
| 2020 | -20.4 | -0.34 | 5.80 | 536.97 | - |
| 2021 | -7.5 | -0.34 | 2.02 | 176.41 | - |
| 2022 | -4.7 | 0.17 | 1.03 | 10.12 | - |
| 2023 | -2.1 | -0.08 | 0.74 | 3,745.44 | - |
| 2024 | -0.5 | -0.01 | 0.44 | 2,743.40 | - |
| 2025 | -1.9 | 0.00 | 2.12 | 14,614.52 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.53 | $657K | $-121.26M | -18456% |
| 2020 | $-0.84 | $7.76M | $-198.53M | -2559.7% |
| 2021 | $-1.03 | $10.65M | $-285.5M | -2680.8% |
| 2022 | $-0.74 | $84.68M | $-4.75M | -5.6% |
| 2023 | $-0.93 | $130K | $-234.63M | -180486.2% |
| 2024 | $-1.31 | $61K | $-342.99M | -562285.2% |
| 2025 | $-16.06 | $36K | $-274.45M | -762355.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-9.71 | $-9.79 – $-9.62 | $15.33K | $15.33K – $15.33K | 4 |
| 2027 | $-9.02 | $-11.69 – $-7.54 | $2.51M | $2.51M – $2.51M | 4 |
| 2028 | $-6.43 | $-7.20 – $-5.71 | $52.64M | $52M – $53.27M | 3 |
| 2029 | $-5.88 | $-5.88 – $-5.88 | $190.23M | $190.23M – $190.23M | 1 |
| 2030 | $-4.11 | $-4.11 – $-4.11 | $280M | $280M – $280M | 1 |
